Magnimus Pharmaceutical Industries Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.53 Cr
as on 16-11-2024
- Revenue 170.11%
(FY 2023)
- Profit 42.33%
(FY 2023)
- Ebitda 111.12%
(FY 2023)
- Net Worth 40.60%
(FY 2023)
- Total Assets 232.36%
(FY 2023)
About Magnimus Pharmaceutical Industries
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.53 Cr.
Karan Goyal and Subhash Chander serve as directors at the Company.
- CIN/LLPIN
U24110PB2019PTC049085
- Company No.
049085
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Tarn Taran, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Magnimus Pharmaceutical Industries Private Limited offer?
Magnimus Pharmaceutical Industries Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Cardiovascular Drugs & Medication, Antianginal Drugs, Blood Pressure Medicine, Cholesterol Medicine, Kidney Drugs, Pain Relief Drugs & Pharmaceuticals, Diclofenac.
Who are the key members and board of directors at Magnimus Pharmaceutical Industries?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Goyal  | Director | 24-May-2023 | Current |
| Subhash Chander | Director | 24-May-2023 | Current |
Financial Performance of Magnimus Pharmaceutical Industries.
Magnimus Pharmaceutical Industries Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 170.11% increase. The company also saw a substantial improvement in profitability, with a 42.33% increase in profit. The company's net worth Soared by an impressive increase of 40.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Magnimus Pharmaceutical Industries?
Unlock access to Magnimus Pharmaceutical Industries's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Perfect Mettcast Private LimitedActive 18 years 7 monthsKaran Goyal and Subhash Chander are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Mar 2023 | ₹5.50 M | Open |
Others Creation Date: 29 Jul 2022 | ₹9.80 M | Open |
How Many Employees Work at Magnimus Pharmaceutical Industries?
Unlock and access historical data on people associated with Magnimus Pharmaceutical Industries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Magnimus Pharmaceutical Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Magnimus Pharmaceutical Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
